Keyphrases
Annualized Relapse Rate
14%
Cumulative Incidence
42%
Cytokine Release Syndrome
100%
Cytokine Signaling
14%
Disease-free
14%
Disease-specific Mortality
14%
Graft-versus-host Disease (GvHD)
100%
Graft-versus-host Disease Prophylaxis
42%
Haploidentical Hematopoietic Stem Cell Transplantation
57%
Haploidentical Transplantation
100%
Hematological Malignancies
14%
Interferon-γ
14%
Interleukin-6
14%
Itacitinib
100%
Janus Kinase 1 (JAK1)
28%
Life-threatening Complications
14%
Low Dose Rate
14%
Non-relapse Mortality
28%
Overall Survival
42%
Pathophysiology
14%
Post-transplantation Cyclophosphamide (PTCy)
14%
Primary Graft Dysfunction
14%
Relapse-free Survival
14%
Selective Inhibitor
14%
Single-arm Study
14%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Graft Versus Host Disease
14%
Chronic Graft Versus Host Disease
28%
Cyclophosphamide
14%
Cytokine
14%
Cytokine Release Syndrome
100%
Gamma Interferon
14%
Graft Failure
14%
Graft Versus Host Reaction
100%
Hematologic Malignancy
14%
Interleukin 6
14%
Itacitinib
100%
Janus Kinase 1
28%
Overall Survival
42%
Pathophysiology
14%
Recurrence Free Survival
14%
Immunology and Microbiology
Acute Graft Versus Host Disease
14%
Arm
14%
Cell Transplantation
57%
Chronic Graft Versus Host Disease
28%
Cyclophosphamide
14%
Cytokine
14%
Cytokine Release Syndrome
100%
Graft-Versus-Host Disease
100%
Hematopoietic Cell
57%
Interferon Gamma
14%
Interleukin 6
14%
Overall Survival
42%
Personal Experience
14%
Recurrence Free Survival
14%